keyword
MENU ▼
Read by QxMD icon Read
search

Non small cell lung cancer

keyword
https://www.readbyqxmd.com/read/28738500/mir-101-3p-inhibits-the-growth-and-metastasis-of-non-small-cell-lung-cancer-through-blocking-pi3k-akt-signal-pathway-by-targeting-malat-1
#1
Xiaoqiang Zhang, Xianju He, Yunbing Liu, Huiqing Zhang, He Chen, Shanxian Guo, Yonggang Liang
BACKGROUND: MiR-101-3p is an important tumor suppressor miRNA in many human cancers. This study was to investigate the role of miR-101-3p in the progression of non-small cell lung cancer (NSCLC) and its potential underlying mechanism. METHODS: In this study, the endogenous expression of miR-101-3p or MALAT-1 in cells was modulated by cell transfection assays. The regulatory interaction of miR-101-3p and MALAT-1 was examined by Luciferase reporter gene and RNA pull-down assays...
July 18, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28737828/taz-inhibition-restores-sensitivity-of-cisplatin-via-akt-mtor-signaling-in-lung-adenocarcinoma
#2
Wei Xu, Yunyan Wei, Yue Li, Yuan Yin, Weiwei Yuan, Yan Yang, Weihong Zhao, Jianqing Wu
The cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced non-small cell lung cancer (NSCLC), however, many patients exhibit acquired drug resistance. Transcriptional co-activator with PDZ binding motif (TAZ) is an oncogene in lung cancer, important for lung tumorigenesis and metastasis. Recently, it was revealed that TAZ upregulation confers resistance against a diverse range of cytotoxic agents. The present study aimed to investigate whether TAZ is involved in cisplatin sensitivity in lung adenocarcinoma...
July 24, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28737782/ferrocene-cinchona-hybrids-with-triazolyl-chalcone-linkers-act-as-pro-oxidants-and-sensitize-human-cancer-cell-lines-to-paclitaxel
#3
Ana Podolski-Renić, Szilvia Bősze, Jelena Dinić, László Kocsis, Ferenc Hudecz, Antal Csámpai, Milica Pešić
Recently, we demonstrated that ferrocene-containing compounds with a cinchona moiety displayed marked anticancer activity. Here we report on the effects of the most promising isomers encompassing quinine- (compounds 4 and 5) and quinidine-epimers (compounds 6 and 7) - synthesized using improved methods providing controlled diastereoselectivity - in three different human multidrug resistant (MDR) cancer cell lines and their sensitive counterparts (non-small cell lung carcinoma NCI-H460/R/NCI-H460, colorectal carcinoma DLD1-TxR/DLD1 and glioblastoma U87-TxR/U87)...
July 24, 2017: Metallomics: Integrated Biometal Science
https://www.readbyqxmd.com/read/28736761/phase-ii-study-of-dovitinib-in-patients-progressing-on-anti-vascular-endothelial-growth-factor-therapy
#4
Thomas J Semrad, Edward J Kim, Michael S Tanaka, Jacob Sands, Chris Roberts, Rebekah A Burich, Yu Li, David R Gandara, Primo Lara, Philip C Mack
BACKGROUND: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-vascular endothelial growth factor (VEGF) therapy. We tested dovitinib, an inhibitor of both FGF and VEGF receptors, in patients progressing on anti-VEGF treatment. METHODS: Patients with measurable advanced colorectal or non-small cell lung cancer with progression despite anti-VEGF treatment within 56 days, good performance status and adequate organ function were eligible...
2017: Cancer Treat Res Commun
https://www.readbyqxmd.com/read/28736363/-clinical-characteristics-and-risk-factors-affecting-outcomes-of-elderly-patients-with-non-small-cell-lung-cancer-complicated-by-chronic-obstructive-pulmonary-disease
#5
Peng Wang, Dong Zhang, Xue-Guang Guo, Bao-Jun Sun, Xiang-Qun Fang, Ge-Ping Qu, Chang-Ting Liu
OBJECTIVE: To investigate the clinical features, treatment strategy and risk factors affecting the prognosis of elderly patients with non-small cell lung cancer (NSCLC) complicated by chronic obstructive pulmonary disease (COPD). METHODS: We retrospectively analyzed the data of elderly patietns (>60 years) with newly diagnosed NSCLC complicated by COPD at the Geriatric Institution of General Hospital of PLA between January, 2000 and June, 2015. The clinical data collected included history of smoking, pulmonary function test results, initial treatments, TNM stage, chief complaints, comorbidities and laboratory tests...
July 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28735769/the-elderly-are-less-likely-to-receive-recommended-radical-radiotherapy-for-non-small-cell-lung-cancer
#6
J McAleese, S Baluch, K Drinkwater, P Bassett, G G Hanna
AIMS: The National Institute for Healthcare Excellence recommends continuous hyperfractionated, accelerated radiotherapy (CHART), concurrent chemoradiation (cCRT) and stereotactic ablative radiotherapy (SABR) for appropriate patients with non-small cell lung cancer (NSCLC), but these are not universally available in all UK radiotherapy centres. Reduced access to these treatments may be contributing to reduced survival, with the concern that elderly patients are less likely to receive guideline-recommended therapy (GRT)...
July 20, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28734822/icotinib-versus-whole-brain-irradiation-in-patients-with-egfr-mutant-non-small-cell-lung-cancer-and-multiple-brain-metastases-brain-a-multicentre-phase-3-open-label-parallel-randomised-controlled-trial
#7
Jin-Ji Yang, Caicun Zhou, Yisheng Huang, Jifeng Feng, Sun Lu, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng, Chengping Hu, Gongyan Chen, Li Zhang, Xiaoqing Liu, Hong Hong Yan, Fen Lai Tan, Wenzhao Zhong, Yi-Long Wu
BACKGROUND: For patients with non-small-cell lung cancer (NSCLC) and multiple brain metastases, whole-brain irradiation (WBI) is a standard-of-care treatment, but its effects on neurocognition are complex and concerning. We compared the efficacy of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), icotinib, versus WBI with or without chemotherapy in a phase 3 trial of patients with EGFR-mutant NSCLC and multiple brain metastases. METHODS: We did a multicentre, open-label, parallel randomised controlled trial (BRAIN) at 17 hospitals in China...
July 19, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28734820/brain-metastases-in-patients-with-egfr-mutant-non-small-cell-lung-cancer
#8
Rafael Rosell, Niki Karachaliou
No abstract text is available yet for this article.
July 19, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28734581/discovery-of-r-5-benzo-d-1-3-dioxol-5-yl-7-1-vinylsulfonyl-pyrrolidin-2-yl-methyl-7h-pyrrolo-2-3-d-pyrimidin-4-amine-b6-as-a-potent-bmx-inhibitor-for-the-treatment-of-nsclc
#9
Linhong He, Da Li, Chufeng Zhang, Peng Bai, Lijuan Chen
Described as a Btk inhibitor, ibrutinib also potently inhibits Bmx and EGFR, two good targets for lung cancer. Owing to its high CLogP (4.07) and low aqueous solubility (<0.01mg/ml), resulting in unfavorable bioavailability, ibrutinib requires high dosages to achieve good clinical response in the treatment of non-small cell lung cancer (NSCLC). In our effort to improve the CLogP of ibrutinib by structural optimization led to the discovery of a potent anti-cancer agent B6, with beneficial physicochemical parameters (CLogP=2...
July 4, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28733892/comparison-of-recist-to-immune-related-response-criteria-in-patients-with-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors
#10
Hee Kyung Kim, Mi Hwa Heo, Han Sang Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
PURPOSE: Given that immune-related response in non-small cell lung cancer (NSCLC) has not been well evaluated, we assessed tumor response using the response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1) and immune-related response criteria (irRC) to identify atypical responses in patients with advanced NSCLC treated with immunotherapeutic agents. METHODS: Patients received immune-checkpoint inhibitors (pembrolizumab, atezolizumab, nivolumab, and durvalumab plus tremelimumab) to treat metastatic or recurrent NSCLC after failed platinum-based chemotherapy...
July 21, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28733723/an-individualized-radiation-dose-escalation-trial-in-non-small-cell-lung-cancer-based-on-fdg-pet-imaging
#11
Marie Wanet, Antoine Delor, François-Xavier Hanin, Benoît Ghaye, Aline Van Maanen, Vincent Remouchamps, Christian Clermont, Samuel Goossens, John Aldo Lee, Guillaume Janssens, Anne Bol, Xavier Geets
AIM: The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. PATIENTS AND METHODS: A total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes)...
July 21, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28733702/anti-invasive-effects-of-cxcr4-and-fak-inhibitors-in-non-small-cell-lung-carcinomas-with-mutually-inactivated-p53-and-pten-tumor-suppressors
#12
Miodrag Dragoj, Jasna Bankovic, Evangelia Sereti, Sofija Jovanovic Stojanov, Konstantinos Dimas, Milica Pesic, Tijana Stankovic
Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. At the time of diagnosis, a large percentage of NSCLC patients have already developed metastasis, responsible for extremely high mortality rates. CXCR4 receptor and focal adhesion kinase (FAK) are known to regulate such invasive cancer behavior. Their expression is downregulated by p53 and PTEN tumor suppressors which are commonly co-inactivated in NSCLC patients and contribute to metastasis. Therefore, targeting CXCR4 or FAK seems to be a promising strategy in suppressing metastatic spread of p53/PTEN deficient NSCLCs...
July 22, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28733559/dynamics-of-egfr-mutations-in-plasma-recapitulates-the-clinical-response-to-egfr-tkis-in-nsclc-patients
#13
Liwen Xiong, Shaohua Cui, Jingyan Ding, Yun Sun, Longfu Zhang, Yizhuo Zhao, Aiqin Gu, Tianqing Chu, Huimin Wang, Hua Zhong, Xin Ye, Yi Gu, Xin Zhang, Min Hu, Liyan Jiang
OBJECTIVES: Genomic profiling using plasma cell-free DNA (cfDNA) represents a non-invasive alternative to tumor re-biopsy, which is challenging in clinical practice. The feasibility of dynamically monitoring epidermal growth factor receptor (EGFR) mutation status using serial plasma samples from non-small cell lung cancer (NSCLC) patients treated by tyrosine kinase inhibitors (TKIs) and its application in tracking clinical response and detection of resistance were investigated. PATIENTS AND METHODS: Forty-five NSCLC patients with EGFR mutation-positive pre-TKI plasma and at least two post-TKI plasma collections were recruited to this study...
July 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28733555/clinicopathological-and-prognostic-significance-of-circulating-tumor-cells-in-patients-with-lung-cancer-a-meta-analysis
#14
Tingjuan Xu, Guodong Shen, Min Cheng, Weiping Xu, Gan Shen, Shilian Hu
BACKGROUND: The prognostic significance of circulating tumor cells in patients with lung cancer is controversial. Therefore, we aimed to comprehensively and quantitatively assess the prognostic role of CTCs in patients with lung cancer. METHODS: The relevant literature was searched using PubMed, the Cochrane database and the China National Knowledge Internet database (up to June 2016). Using Review Manager 5.1.2, a meta-analysis was performed using hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) as effect values...
July 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28733269/the-current-role-of-whole-brain-radiation-therapy-in-non-small-cell-lung-cancer-patients
#15
REVIEW
Gokoulakrichenane Loganadane, Lizza Hendriks, Cécile Le Péchoux, Antonin Levy
The incidence of brain metastases (BM) has increased in non-small cell lung cancer (NSCLC) patients as a result of better systemic disease control and advances in imaging modalities. Whole brain radiation therapy (WBRT) has been the mainstay treatment of multiple symptomatic brain metastases for years. A number of recent publications questioned its place in absence of survival and quality of life benefit (QoL) and the possible risk of long-term neurotoxicity. Omission or deferral of WBRT, alongside with strategies consisting of radiosurgery (SRS) or the delivery of systemic therapies alone, are more and more proposed...
July 18, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28733185/fdg-pet-parameters-as-predictors-of-pathologic-response-and-nodal-clearance-in-patients-with-stage-iii-non-small-cell-lung-cancer-receiving-neoadjuvant-chemoradiation-and-surgery
#16
Andrea L Arnett, Ann T Packard, Kristin Mara, Aaron S Mansfield, Dennis A Wigle, Michael G Haddock, Sean S Park, Kenneth R Olivier, Yolanda I Garces, Kenneth W Merrell
OBJECTIVE: Pathologic complete response (pCR) following neoadjuvant chemoradiation (CRT) is associated with improved outcomes in stage III non-small cell lung cancer. Conflicting results exist regarding the value of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting pCR. This study evaluated the association between post-CRT FDG-PET and pCR using novel FDG-PET parameters. METHODS AND MATERIALS: This retrospective study included patients treated with CRT and resection...
April 19, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28732516/application-of-the-new-8th-tnm-staging-system-for-non-small-cell-lung-cancer-treated-with-curative-concurrent-chemoradiotherapy
#17
Hoon Sik Choi, Bae Kwon Jeong, Hojin Jeong, Yun Hee Lee, In Bong Ha, Jin Ho Song, Ki Mun Kang
BACKGROUND: The eighth tumor, node, metastasis (TNM) staging system (8-TNM) for non-small cell lung cancer (NSCLC) was newly released in 2015. This system had limitation because most patients included in the analysis were treated with surgery. Therefore, it might be difficult to reflect prognosis of patients treated with curative concurrent chemoradiotherapy (CCRT). Purpose of this study was to investigate clinical impact of the newly published 8-TNM compared to the current seventh TNM staging system (7-TNM) for locally advanced NSCLC patients treated with CCRT...
July 21, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28732383/radiation-alters-pd-l1-nkg2d-ligand-levels-in-lung-cancer-cells-and-leads-to-immune-escape-from-nk-cell-cytotoxicity-via-il-6-mek-erk-signaling-pathway
#18
Ming Jing Shen, Li Jun Xu, Li Yang, Ying Tsai, Peter C Keng, Yongbing Chen, Soo Ok Lee, Yuhchyau Chen
We investigated whether radiation influences the susceptibility of non-small cell lung cancer (NSCLC) cells to NK cell mediated cytotoxicity. We found radiation treatment increased expression of programmed cell death ligand 1 (PD-L1), but decreased NK group 2, member D (NKG2D) ligand expressions in A549 and H157 NSCLC cells. Both types of changes would have protected tumor cells from the cytotoxic action of NK cells. Consistently, we detected similar alteration in these molecules in radioresistant A549R26-1 and H157R24-1 subline cells...
July 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28732214/crispr-cas9-technology-based-xenograft-tumors-as-candidate-reference-materials-for-multiple-eml4-alk-rearrangements-testing
#19
Rongxue Peng, Rui Zhang, Guigao Lin, Xin Yang, Ziyang Li, Kuo Zhang, Jiawei Zhang, Jinming Li
The echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (EML4-ALK) rearrangement is an important biomarker that plays a pivotal role in therapeutic decision making for non-small-cell lung cancer (NSCLC) patients. Ensuring accuracy and reproducibility of EML4-ALK testing by fluorescence in situ hybridization, immunohistochemistry, RT-PCR, and next-generation sequencing requires reliable reference materials for monitoring assay sensitivity and specificity...
July 18, 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/28732026/investigation-of-opioid-use-and-long-term-oncologic-outcomes-for-non-small-cell-lung-cancer-patients-treated-with-surgery
#20
Tak Kyu Oh, Jae Hyun Jeon, Jong Mog Lee, Moon Soo Kim, Jee Hee Kim, Hyeyeon Cho, Seong-Eun Kim, Woosik Eom
Opioids are commonly used for postoperative pain control in cancer patients. In addition to pain control, an association between opioid use and long-term oncologic outcomes, such as recurrence or overall survival, has been postulated. The aim of this study was to determine whether postoperative opioid use in patients with non-small cell lung cancer is associated with long-term oncologic outcomes, including recurrence and death. Data obtained from 1009 medical records of patients who underwent curative resection at the National Cancer Center, Korea between January 2006 and December 2010 were retrospectively analyzed...
2017: PloS One
keyword
keyword
8878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"